search
Back to results

Fluoroscopy Reduction or Elimination in CIED Implants

Primary Purpose

Bradycardia, Tachycardia, Ventricular, Heart Failure

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Fluoroscopy reduction
Sponsored by
Université de Sherbrooke
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bradycardia focused on measuring CIED implant, Fluoroscopy reduction

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • CIED implants

Exclusion Criteria:

  • Patients with an urgent life-threatening indication requiring an urgent CIED implant.
  • Patients with known venous system abnormalities (as venous occlusion or abandoned non-accessible leads).

Sites / Locations

  • CHUS FleurimontRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Non fluoroscopy CIED implant

Arm Description

Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system

Outcomes

Primary Outcome Measures

Fluoroscopy time needed to implant a CIED while using 3-D mapping systems to reduce fluoroscopy exposure
Fluoroscopy time while implanting a CIED
Peak skin dose of radiation exposure during CIED implant
Radiation exposure expressed as total Cumulative Air Kerma (mGy)
Radiation exposure (kerma-area product) during CIED implant
Total Dose Area Product (uGy-m2)
Total procedural time
Time of the patient entering the lab, to the time the patient exits the lab
Safety issues arising because of reduction of fluoroscopy
Complications arising while using a reduced fluoroscopy environment

Secondary Outcome Measures

Detailed 3-D mapping needed Y/N
Is it necessary to create a detailed anatomy to navigate leads without fluoroscopy
Current of lesion at desired implant fixation site (Y/N)
If current of lesion is necessary to ascertain that the fixation mechanism is already deployed

Full Information

First Posted
May 12, 2021
Last Updated
May 25, 2022
Sponsor
Université de Sherbrooke
search

1. Study Identification

Unique Protocol Identification Number
NCT04919733
Brief Title
Fluoroscopy Reduction or Elimination in CIED Implants
Official Title
Fluoroscopy Reduction or Elimination in CIED Implants
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 3, 2020 (Actual)
Primary Completion Date
January 3, 2024 (Anticipated)
Study Completion Date
March 3, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Université de Sherbrooke

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
CIED implants require different amounts of fluoroscopy; using 3-D mapping systems, these times could be reduced to near zero fluoroscopy. The investigators aim to describe to what extent fluoroscopy times are reduced on a routine basis on CIED implants
Detailed Description
Patients with either brady arrhythmias, tachyarrhythmias, heart failure or primary prevention of sudden death receive a cardiac implantable electronic device (CIED) as a standard of care based on guideline indications. All implants require X-ray equipment to visualize the advancement and positioning of leads in different heart chambers. To date only anecdotical cases have been reported in the literature, of implants without fluoroscopy, mostly pregnant patients with a CIED indication that could not wait for implant after delivery or some rare situations where ultrasound was used to guide the leads trough the heart. There are two reported experiences using St-Jude Abbot 3-D NavX system; where 35 (ICD and pacemakers) and 15 (VVI pacemakers only) CIED patients were respectively approached with times reported to right ventricular lead implant of 18 +/- 22 minutes and atrial lead implant of 16 +/- 9 minutes, in 89% of cases a final fluoroscopy shot was deemed necessary (in 16% of patients it was needed to correct final position); in the second report with VVI only pacemakers, the implant of a single lead was 10.1 +/- 5.4 minutes, and the total procedure duration was 59.3 +/- 15.16 minutes -one patient needed fluoroscopy-, this last cohort was compared to previous 15 VVI pacemaker patients implanted under fluoroscopy, with control times of 51.5 +/- 12.3 minutes6 (p=ns); both studies reported around 10 minutes needed to obtain right chamber anatomies. There is a little more experience on biventricular implants with two reports one single center and then the same Italian group with a multicenter study achieving a significant reduction in fluoroscopy times: from 16 minutes to 4 minutes (ranges from 11-26 to 0.3-10.4 minutes) compared with a historical control, and with the same success rates to left lead implants; even in experienced centers (more than 10 previous implants) the median time was 3 minutes of fluoroscopy when a St-Jude Abbot NavX system was used. The advancement on 3-D mapping systems, allows nowadays to reduce and even eliminate the need of X-rays for most of ablation procedures, where the catheters advancement, positioning and navigation through the four heart chambers is accomplished with minimal or no irradiation to the patients and to the health care personnel. The hypothesis is that use of standard 3-D mapping systems to achieve CIED implants is feasible, safe, and that could be accomplished in a time efficient way. This will be the first large report for all type of CIED implants and with all available 3-D mapping system utilization; the investigators will try also to define if a complete reconstructed virtual anatomy is needed of if a rough anatomy is sufficient to achieve the implant, and speed procedure times.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bradycardia, Tachycardia, Ventricular, Heart Failure
Keywords
CIED implant, Fluoroscopy reduction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
To ascertain if the use of 3-D mapping systems reduces the need of fluoroscopy during a CIED (pacemaker or defibrillator) implant
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Non fluoroscopy CIED implant
Arm Type
Experimental
Arm Description
Try to reduce as much as possible the fluoroscopy needed to implant a CIED pacemaker or defibrillator using a 3-D mapping system
Intervention Type
Device
Intervention Name(s)
Fluoroscopy reduction
Intervention Description
To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
Primary Outcome Measure Information:
Title
Fluoroscopy time needed to implant a CIED while using 3-D mapping systems to reduce fluoroscopy exposure
Description
Fluoroscopy time while implanting a CIED
Time Frame
During implant procedure
Title
Peak skin dose of radiation exposure during CIED implant
Description
Radiation exposure expressed as total Cumulative Air Kerma (mGy)
Time Frame
During implant procedure
Title
Radiation exposure (kerma-area product) during CIED implant
Description
Total Dose Area Product (uGy-m2)
Time Frame
During implant procedure
Title
Total procedural time
Description
Time of the patient entering the lab, to the time the patient exits the lab
Time Frame
During implant procedure
Title
Safety issues arising because of reduction of fluoroscopy
Description
Complications arising while using a reduced fluoroscopy environment
Time Frame
During implant procedure
Secondary Outcome Measure Information:
Title
Detailed 3-D mapping needed Y/N
Description
Is it necessary to create a detailed anatomy to navigate leads without fluoroscopy
Time Frame
During implant procedure
Title
Current of lesion at desired implant fixation site (Y/N)
Description
If current of lesion is necessary to ascertain that the fixation mechanism is already deployed
Time Frame
During implant procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: CIED implants Exclusion Criteria: Patients with an urgent life-threatening indication requiring an urgent CIED implant. Patients with known venous system abnormalities (as venous occlusion or abandoned non-accessible leads).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Felix AYALA PAREDES, MD, PhD
Phone
819 346 1110
Ext
74947
Email
felix.ayala-paredes@usherbrooke.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Claude JEAN, RN
Phone
819 346 1110
Ext
16317
Email
claude.jean.ciussse-chus@ssss.gouv.qc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felix AYALA PAREDES, MD, PhD
Organizational Affiliation
University of Shebrooke Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHUS Fleurimont
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
FELIX AYALA PAREDES, MD PhD
Phone
+1 819 3461110
Ext
74947
Email
felix.ayala-paredes@usherbrooke.ca
First Name & Middle Initial & Last Name & Degree
Claude JEAN, RN
Phone
+1 819 3461110
Ext
16317
Email
claude.jean.ciussse-chus@ssss.gouv.qc.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fluoroscopy Reduction or Elimination in CIED Implants

We'll reach out to this number within 24 hrs